Henlius Aims to Launch More Biosimilars in US, EU

Jason Zhu Jun, Executive Director and CEO of Chinese drugmaker Shanghai Henlius Biotech, says the Hong Kong-listed firm is gaining more confidence among international partners as it focuses on expanding its offerings the US and the EU. He speaks exclusively with David Ingles and Yvonne Man on "Bloom...

Redirecting to full article...